文献速递抗栓抗凝管理药物不良反应与药物警戒

经导管主动脉瓣置换术患者的药物管理

Medication Management of Patients Undergoing Transcatheter Aortic Valve Replacement.
PubMed 文献 · Pharmacotherapy · 2017-12-25

本文综述经导管主动脉瓣置换术(TAVR)围术期药物治疗的关键文献。主动脉瓣狭窄是最常见的瓣膜性心脏病,TAVR已更广泛用于中高危患者。卒中为TAVR常见并发症且与死亡率升高相关,围术期及术后需抗栓治疗,但最佳平衡血栓栓塞与出血的方案尚未确定。

要点

  • TAVR围术期用药管理对瓣膜植入成功和减少不良事件至关重要
  • 卒中仍是TAVR常见并发症之一,与死亡率增加相关
  • 合并需口服抗凝疾病或发生瓣下血栓者抗栓管理面临独特挑战

核心结论

  • TAVR围术期及术后抗栓治疗是必要的,但最能减少血栓栓塞事件并兼顾出血并发症的方案尚未明确。
  • 抗血小板与抗凝治疗应谨慎平衡,尤其对合并需口服抗凝疾病或发生瓣下血栓的患者。

研究设计与样本

  • 本文为综述,汇总支持TAVR患者药物治疗管理的关键文献。

主要发现

  • 主动脉瓣狭窄是最常见的瓣膜性心脏病,需详细诊断评估以分期和分级。
  • 药物治疗与瓣膜成形术不能延缓或逆转疾病进展;外科主动脉瓣置换(SAVR)可治愈但对部分人群有显著局限。
  • TAVR已更广泛用于中危或高手术风险患者。
  • 卒中仍是TAVR最常见并发症之一,并与死亡率增加相关。

临床怎么用

  • TAVR患者围术期用药管理应围绕成功植入瓣膜和减少不良事件进行。
  • 对需口服抗凝或发生瓣下血栓者,应审慎权衡抗血小板与抗凝治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aortic stenosis (AS) is the most common form of valvular heart disease. A detailed diagnostic workup is necessary to promptly stage and classify disease severity to determine optimal management. Medical therapy and valvuloplasty are options that fail to delay or reverse disease progression. Surgical aortic valve replacement (SAVR) is curative but has significant limitations for some patient populations. A newer option, transcatheter aortic valve replacement (TAVR), has become more widely available to patients with intermediate- or high-operative risk. Periprocedural medication management is imperative for successful valve implantation and to minimize adverse events. Stroke remains one of the most common complications of TAVR and is associated with increased mortality. Thus, intra- and postprocedural antithrombotic therapy is required, although the regimen that best minimizes thromboembolic events and bleeding complications has yet to be defined. Patients undergoing TAVR with comorbid conditions requiring oral anticoagulation or individuals who develop subvalvular thromboses pose unique challenges. Antiplatelet and anticoagulant therapy should be carefully balanced. This article summarizes key literature supporting the pharmacologic management of patients receiving TAVR.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Kalich BA, Allender JE, Hollis IB, et al. Medication Management of Patients Undergoing Transcatheter Aortic Valve Replacement. Pharmacotherapy. 2017. PMID: 29121410. doi:10.1002/phar.2056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。